Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting. J of Skin. 2026;10(2):s730. doi:10.25251/7mx6d484